Switch theme
Sign up to access all valuation multiples
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
2000
49
LTM Revenue $9.3M
LTM EBITDA -$47.0M
$6.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Curis has a last 12-month revenue of $9.3M and a last 12-month EBITDA of -$47.0M.
In the most recent fiscal year, Curis achieved revenue of $10.0M and an EBITDA of -$45.1M.
Curis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Curis valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $10.0M | $9.6M | XXX | XXX | XXX |
| Gross Profit | $10.1M | $9.9M | XXX | XXX | XXX |
| Gross Margin | 101% | 103% | XXX | XXX | XXX |
| EBITDA | -$45.1M | -$46.0M | XXX | XXX | XXX |
| EBITDA Margin | -450% | -477% | XXX | XXX | XXX |
| Net Profit | -$45.4M | -$56.7M | XXX | XXX | XXX |
| Net Margin | -453% | -588% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of March 14, 2025, Curis's stock price is $3.
Curis has current market cap of $24.0M, and EV of $6.5M.
See Curis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6.5M | $24.0M | XXX | XXX | XXX | XXX | $-6.40 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of March 14, 2025, Curis has market cap of $24.0M and EV of $6.5M.
Curis's trades at 0.7x LTM EV/Revenue multiple, and -0.1x LTM EBITDA.
Analysts estimate Curis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Curis and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $6.5M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | -0.1x | XXX | XXX | XXX |
| P/E | -0.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCuris's NTM/LTM revenue growth is -8%
Curis's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $1.2M for the same period.
Over next 12 months, Curis's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Curis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Curis and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -4% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -477% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -486% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.2M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 186% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 394% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 580% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Curis acquired XXX companies to date.
Last acquisition by Curis was XXXXXXXX, XXXXX XXXXX XXXXXX . Curis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Curis founded? | Curis was founded in 2000. |
| Where is Curis headquartered? | Curis is headquartered in United States of America. |
| How many employees does Curis have? | As of today, Curis has 49 employees. |
| Who is the CEO of Curis? | Curis's CEO is Mr. James E. Dentzer. |
| Is Curis publicy listed? | Yes, Curis is a public company listed on NAS. |
| What is the stock symbol of Curis? | Curis trades under CRIS ticker. |
| When did Curis go public? | Curis went public in 2000. |
| Who are competitors of Curis? | Similar companies to Curis include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Curis? | Curis's current market cap is $24.0M |
| What is the current revenue of Curis? | Curis's last 12-month revenue is $9.3M. |
| What is the current EBITDA of Curis? | Curis's last 12-month EBITDA is -$47.0M. |
| What is the current EV/Revenue multiple of Curis? | Current revenue multiple of Curis is 0.7x. |
| What is the current EV/EBITDA multiple of Curis? | Current EBITDA multiple of Curis is -0.1x. |
| What is the current revenue growth of Curis? | Curis revenue growth between 2023 and 2024 was -4%. |
| Is Curis profitable? | Yes, Curis is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
